United States: Withdrawal Of Drug Approval Highlights Risk Of Accelerated Approval Pathway - Sheppard Mullin Richter & Hampton

On April 5, 2023, the U.S. Food and Drug Administration ("FDA") announced its decision to withdraw the approval of Makena® hydroxyprogesterone caproate injection ("Makena"...